Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2022

Disclosure Of Compensation Related Costs Share-based Payments [Abstract]

Summary of Share-Based Compensation Expense

The amount of share-based compensation expense recognized by the Company by location in its statements of operations for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Cost of revenues	$	35	$	23	$	94		56
Sales and marketing		1,074		515		3,258		1,608
General and administrative		939		1,368		2,950		4,368
Research and development		130		55		331		134
Total	$	2,178	$	1,961	$	6,633	$	6,166

Summary of Stock Option Activity

The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2022:

					Aggregate
	Number of	Weighted-		Weighted-	average
	Shares under	average		Remaining	Intrinsic
	Option	Exercise Price		Contractual	Value
	(in thousands)	per Option		Life (in years)	(in thousands)
Outstanding at December 31, 2021	1,499	$	4.01
Granted	—	$	—
Exercised	(51)	$	1.01
Forfeited	(24)	$	13.41
Outstanding at September 30, 2022	1,424	$	3.96	7.2	$	1,260
Exercisable at September 30, 2022	913	$	4.62	6.9	$	708
Vested and expected to vest at September 30, 2022	1,424	$	3.96	7.2	$	1,260

Summary of Restricted Stock Units and Performance Restricted Stock Units Activity

The following table summarizes the Company’s restricted stock unit and performance restricted stock unit activity for September 30, 2022:

	Non-vested		Weighted-	Non-vested		Weighted-
	Restricted		average	Performance Restricted		average
	Stock Units		Grant-date	Stock Units		Grant-date
	(in thousands)		Fair Value	(in thousands)		Fair Value
Non-vested at December 31, 2021	1,729	$	7.29	395	$	6.77
Granted	2,775	$	3.32	—	$	—
Vested	(613)	$	7.64	—	$	—
Forfeited	(226)	$	6.12	—	$	—
Non-vested at September 30, 2022	3,665	$	4.29	395	$	6.77

Summary of Inputs and Assumptions used to Estimated Grant-date Fair Value of Performance Restricted Stock Units

The Company did not grant performance restricted stock units during the period ended September 30, 2022. For the period ended December 31, 2021, the grant-date fair value of the performance restricted stock units was estimated at the time of grant using the following inputs and assumptions in the Monte Carlo simulation valuation model:

		December 31, 2021
Closing price of common stock	$	15.92
Risk-free interest rate		1.15	%
Expected volatility		99.7	%